Top

Diabetologia

Published in:

01-06-2005 | Article

Cellular cholesterol efflux to plasma from moderately hypercholesterolaemic type 1 diabetic patients is enhanced, and is unaffected by simvastatin treatment

Authors: R. de Vries, M. N. Kerstens, W. J. Sluiter, A. K. Groen, A. van Tol, R. P. F. Dullaart

Published in: Diabetologia | Issue 6/2005

Abstract

Aim/hypothesis

Cellular cholesterol efflux to plasma is important in reverse cholesterol transport and may be affected by simvastatin in type 1 diabetes mellitus.

Methods

In 14 moderately hypercholesterolaemic type 1 diabetic and 13 healthy men we determined plasma (apo)lipoproteins, pre-β HDL formation, cholesteryl ester transfer protein (CETP) activity, phospholipid transfer protein (PLTP) activity, cholesterol esterification, cholesteryl ester transfer and the capacity of plasma to induce cholesterol efflux out of Fu5AH cells and fibroblasts. After diet run-in, diabetic patients were randomly treated with simvastatin 10, 20, 40 mg and placebo, once daily each, for 6 weeks in a double-blind crossover design.

Results

Plasma very low density lipid protein (VLDL)+LDL cholesterol, LDL cholesterol, HDL phospholipids, apolipoprotein (apo) A-I, apo B, CETP activity, PLTP activity, cholesterol esterification, cholesteryl ester transfer and the capacity of plasma to induce cholesterol efflux from Fu5AH cells and fibroblasts were higher in diabetic patients. Pre-β HDL formation was unaltered. Simvastatin treatment decreased VLDL+LDL cholesterol, LDL cholesterol, triglycerides and apo B, CETP activity, cholesterol esterification and cholesteryl ester transfer. HDL cholesterol increased and its change was correlated with the change in cholesteryl ester transfer. The ability to promote cholesterol efflux from Fu5AH cells and fibroblasts did not change after simvastatin.

Conclusions/interpretation

The capacity of plasma from moderately hypercholesterolaemic type 1 diabetic patients to induce cholesterol efflux out of Fu5AH cells and fibroblasts is enhanced, probably due to higher apo A-I, HDL phospholipids and PLTP activity. Simvastatin increases HDL cholesterol in type 1 diabetic patients via lowering of plasma cholesteryl ester transfer. The HDL changes after simvastatin do not increase cellular cholesterol efflux further.

Tall AR (1990) Plasma high density lipoproteins. Metabolism and relationship to atherogenesis. J Clin Invest 86:379–384PubMed

Fielding CJ, Fielding PE (1995) Molecular physiology of reverse cholesterol transport. J Lipid Res 36:211–228PubMed

Barter PJ, Rye KA (1993) High density lipoproteins and reverse cholesterol transport. Curr Opin Lipidol 4:210–217

Bruce C, Tall AR (1995) Cholesteryl ester transfer proteins, reverse cholesterol transport, and atherosclerosis. Curr Opin Lipidol 6:311

Eisenberg S (1984) High density lipoprotein metabolism. J Lipid Res 25:1017–1058PubMed

Castro GR, Fielding CJ (1988) Early incorporation of cell-derived cholesterol into pre-β-migrating high-density lipoprotein. Biochemistry 27:25–29CrossRefPubMed

Von Eckardstein A, Huang Y, Assmann G (1994) Physiological role and clinical relevance of high-density lipoprotein subclasses. Curr Opin Lipidol 5:404–416PubMed

Borggreve SE, De Vries R, Dullaart RPF (2003) Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins. Eur J Clin Invest 33:1051–1069CrossRefPubMed

Jauhiainen M, Metso J, Pahlman R, Blomqvist S, Van Tol A, Ehnholm C (1993) Human plasma phospholipid transfer protein causes high density lipoprotein conversion. J Biol Chem 268:4032–4036PubMed

10.

Von Eckardstein A, Jauhiainen M, Huang Y et al (1996) Phospholipid transfer protein mediated conversion of high density lipoproteins generates pre β1-HDL. Biochim Biophys Acta 1301:255–262PubMed

11.

Rye KA, Clay MA, Barter PJ (1999) Remodelling of high density lipoproteins by plasma factors. Atherosclerosis 145:227–238CrossRefPubMed

12.

Krolewski AS, Kosinski EJ, Warram JH et al (1987) Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus. Am J Cardiol 59:750–755CrossRefPubMed

13.

Colhoun HM, Scheek LM, Rubens MB et al (2001) Lipid transfer protein activities in type 1 diabetic patients without renal failure and nondiabetic control subjects and their association with coronary artery calcification. Diabetes 50:652–659PubMed

14.

Colhoun HM, Taskinen MR, Otvos JD, Van Den Berg P, O’Connor J, Van Tol A (2002) Relationship of phospholipid transfer protein activity to HDL and apolipoprotein B-containing lipoproteins in subjects with and without type 1 diabetes. Diabetes 51:3300–3305PubMed

15.

Dullaart RPF (1995) Plasma lipoprotein abnormalities in type 1 (insulin-dependent) diabetes mellitus. Neth J Med 46:44–54CrossRefPubMed

16.

Duell PB, Oram JF, Bierman EL (1991) Nonenzymatic glycosylation of HDL and impaired HDL-receptor-mediated cholesterol efflux. Diabetes 40:377–384PubMed

17.

Jones P, Kafonek S, Laurora I, Hunninghake D (1998) Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin en fluvastatin in patients with hypercholesteremia (the CURVES study). Am J Cardiol 81:582–587CrossRefPubMed

18.

Rustemeijer C, Schouten JA, Janssens ENW, Spooren PFMJ, Van Doormaal JJ (1997) Pravastatin in diabetes-associated hypercholesterolemia. Acta Diabetol 34:294–300CrossRefPubMed

19.

Herd JA, Ballantyne CM, Farmer JA et al (1997) Effects of fluvastatine on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol 80:278–286CrossRefPubMed

20.

4S Study Group (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383–1389

21.

Plehn JF, Davis BR, Sacks FM et al (1999) Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care investigators. Circulation 99:216–223PubMed

22.

Downs LR, Clearfield M, Weis S et al (1998) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas coronary atherosclerosis prevention study. JAMA 279:1615–1622CrossRefPubMed

23.

Ahnadi CE, Berthezène F, Ponsin G (1993) Simvastatin-induced decrease in the transfer of cholesterol esters from high density lipoproteins to very low and low density lipoproteins in normolipidemic subjects. Atherosclerosis 99:219–228PubMed

24.

Schaefer JR, Schweer H, Ikewaki K et al (1999) Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease. Atherosclerosis 144:177–184CrossRefPubMed

25.

Dullaart RPF, Riemens SC, Scheek LM, Van Tol A (1999) Insulin decreases plasma cholesteryl ester transport but not cholesterol esterification in healthy subjects as well as in normotriglyceridemic patients type 2 diabetes. Eur J Clin Invest 29:663–671CrossRefPubMed

26.

Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 18:499–552PubMed

27.

Dullaart RPF, Sluiter WJ, Dikkeschei LD, Hoogenberg K, Van Tol A (1994) Effect of adiposity on plasma lipid transfer protein activities: a possible link between insulin resistance and high density lipoprotein metabolism. Eur J Clin Invest 24:188–194PubMed

28.

Speijer H, Groener JE, Van Ramshorst E, Van Tol A (1991) Different locations of cholesteryl ester transfer protein and phospholipid transfer protein activities in plasma. Atherosclerosis 90:159–168PubMed

29.

Groener JE, Pelton RW, Kostner GM (1986) Improved estimation of cholesteryl ester transfer/exchange activity in serum or plasma. Clin Chem 32:283–286PubMed

30.

Van Haperen R, Van Tol A, Vermeulen P et al (2000) Human plasma phospholipid transfer protein increases the antiatherogenic potential of high density lipoproteins in transgenic mice. Arterioscler Thromb Vasc Biol 20:1082–1088PubMed

31.

Brussaard JH, Dallinga-Thie GM, Groot PHE, Katan MB (1980) Effects of amount and type of dietary fat on serum lipids, lipoproteins and apolipoproteins in man. A controlled 8-week trial. Atherosclerosis 36:515–527PubMed

32.

Hovingh GK, Wijland MJ, Brownlie A et al (2003) The role of the ABCA1 transporter and cholesterol efflux in familial hypoalphalipoproteinemia. J Lipid Res 44:1251–1255CrossRefPubMed

33.

De La Llera-Moya M, Atger V, Paul JL et al (1994) A cell culture system for screening human serum for ability to promote cellular cholesterol efflux. Relations between serum components and efflux, esterification, and transfer. Arterioscler Thromb 14:1056–1065PubMed

34.

Smith PK, Krohn RI, Hermanson GT et al (1985) Measurement of protein using bicinchoninic acid. Ann Biochem 150:76–85CrossRef

35.

Dullaart RPF, Van Tol A (2001) Twenty four hour insulin infusion impairs the ability of plasma from healthy subjects and type 2 diabetic patients to promote cellular cholesterol efflux. Atherosclerosis 157:49–56CrossRefPubMed

36.

Rye KA, Jensen G, Barter PJ, Ehnholm C (1998) Triglyceride-enrichment of high density lipoproteins enhances their remodelling by phospholipid transfer protein. J Lipid Res 39:613–622PubMed

37.

Mann CJ, Yen FT, Grant AM, Bihain BE (1991) Mechanism of plasma cholesteryl ester transfer in hypertriglyceridemia. J Clin Invest 88:2059–2066PubMed

38.

Tato F, Vega F, Tall AR, Grundy SM (1995) Relation between cholesterol transfer protein activities and lipoprotein cholesterol in patients with hypercholesterolemia and combined hyperlipidemia. Arterioscler Thromb Vasc Biol 15:112–120PubMed

39.

Rothblat GH, De La Llera-Moya M, Atger V, Kellner-Weibel G, Williams DL, Phillips MC (1999) Cell cholesterol efflux: integration of old and new observations provides new insights. J Lipid Res 40:781–796PubMed

40.

Yancey PG, Bortnick AE, Kellner-Weibel G, De La Llera-Moya M, Phillips MC, Rothblat GH (2003) Importance of different pathways of cellular cholesterol efflux. Arterioscler Thromb Vasc Biol 23:712–719CrossRefPubMed

41.

Fielding CJ, Bist A, Fielding PE (1999) Intracellular cholesterol transport in synchronized human skin fibroblasts. Biochemistry 38:2506–2513CrossRefPubMed

42.

Denis M, Bissonnette R, Haidar B, Krimbou L, Bouvier M, Genest J (2003) Expression, regulation, and activity of ABCA1 in human cell lines. Mol Genet Metab 78:265–274CrossRefPubMed

43.

Wang N, Lan D, Chen W, Matsuura F, Tall AR (2004) ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc Natl Acad Sci U S A 101:9774–9779CrossRefPubMed

44.

Fournier N, Paul JL, Atger V et al (1997) HDL phospholipid content and composition as a major factor determining cholesterol efflux capacity from Fu5AH cells to human serum. Arterioscler Thromb Vasc Biol 17:2685–2691PubMed

45.

Favari E, Lee M, Calabresi L, Franceschini G, Zimetti F, Kovanen PT (2004) Depletion of pre-beta-high density lipoprotein by human chymase impairs ATP-binding cassette transporter A1—but not scavenger receptor class B type I-mediated lipid efflux to high density lipoprotein. J Biol Chem 279:9930–9936CrossRefPubMed

46.

Oram J, Wolfbauer G, Vecchio G, Albers JJ (2003) Phospholipid transfer protein interacts with and stabilizes ATP-binding cassette transporter A1 and enhances cholesterol efflux from cells. J Biol Chem 26:52379–52385CrossRef

47.

Igau B, Castro G, Clavey V et al (1997) In vivo glycosylated LpA-I subfraction. Evidence for structural and functional alterations. Arterioscler Thromb Vasc Biol 17:2830–2836PubMed

48.

Passarelli M, Shimabukuro AFM, Catanozi S et al (2000) Diminished rate of mouse peritoneal macrophage cholesterol efflux is not related to the degree of HDL glycation in diabetes mellitus. Clin Chim Acta 301:119–134CrossRefPubMed

49.

Le NA, Innis-Whitehouse W, Li X, Bakker-Arkema R, Black D, Brown WV (2000) Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reductions with atorvastatin. Metabolism 49:167–177CrossRefPubMed

50.

Guérin M, Lassel TS, Le Goff W, Farnier M, Chapman MJ (2000) Action of atorvastatin in combined hyperlipidemia. Preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Arterioscler Thromb Vasc Biol 20:189–197PubMed

51.

Guérin M, Egger P, Soudant C et al (2002) Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux. Atherosclerosis 163:287–296CrossRefPubMed

52.

Soedamah-Muthu SS, Colhoun HM, Thomason MJ et al (2003) The effects of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease. Atherosclerosis 167:243–255CrossRefPubMed

53.

Wolfrum S, Jensen KS, Liao JK (2003) Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol 23:729–736CrossRefPubMed

54.

Nofer JR, Kehrel B, Fobker M, Levkau B, Assmann G, Von Eckardstein A (2002) HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis 161:1–16CrossRefPubMed

Title: Cellular cholesterol efflux to plasma from moderately hypercholesterolaemic type 1 diabetic patients is enhanced, and is unaffected by simvastatin treatment
Authors: R. de Vries
M. N. Kerstens
W. J. Sluiter
A. K. Groen
A. van Tol
R. P. F. Dullaart
Publication date: 01-06-2005
Publisher: Springer-Verlag
Published in: Diabetologia / Issue 6/2005
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-005-1760-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Aim/hypothesis

Methods

Results

Conclusions/interpretation

Please log in to get access to this content

Other articles of this Issue 6/2005

Alcohol consumption and type 2 diabetes

Alterations of lipids and apolipoprotein CIII in very low density lipoprotein subspecies in type 2 diabetes

Usefulness of pulse pressure for the detection of extent and severity of coronary artery disease in type 2 diabetic patients with silent myocardial ischaemia at exercise stress test

Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus

Serum high molecular weight complex of adiponectin correlates better with glucose tolerance than total serum adiponectin in Indo-Asian males

EASD News Section June 2005

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials